UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000040636
Receipt number R000046290
Scientific Title Evaluation of quantitative analysis of liver fibrosis by IVIM-DWI and Fibroscan in chronic liver disease.
Date of disclosure of the study information 2020/06/10
Last modified on 2023/12/06 09:56:43

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of quantitative analysis of liver fibrosis by IVIM-DWI and Fibroscan in chronic liver disease.

Acronym

Evaluation of quantitative analysis of liver fibrosis by IVIM-DWI and Fibroscan in chronic liver disease.

Scientific Title

Evaluation of quantitative analysis of liver fibrosis by IVIM-DWI and Fibroscan in chronic liver disease.

Scientific Title:Acronym

Evaluation of quantitative analysis of liver fibrosis by IVIM-DWI and Fibroscan in chronic liver disease.

Region

Japan


Condition

Condition

chronic liverdisease

Classification by specialty

Hepato-biliary-pancreatic medicine Radiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To examine the usefulness of IVIM-DWI as a quantitative evaluation method of liver fibrosis in comparison with Fibroscan.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

To confirm the advantages of IVIM-DWI quantitative evaluation compared with Fibroscan

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Diagnosis

Type of intervention

Device,equipment

Interventions/Control_1

Acquisition of MRI images

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1.Chronic liver impairment is suspected, and MRI of liver, blood test, and Fibroscan were performed. Pathological examination is not mandatory.
2.Hematological tests (hemoglobin, white blood cell count, white blood cell fraction, platelet count), and blood biochemical tests (ALP, total bilirubin, albumin, AST, ALT, total protein, LDH, HbA1C, ChE, total cholesterol, type) 4 collagen and M2GPI are included).
3.Patients who obtained written informed consent from the patient during the echo examination and MRI examination (includ IVIM-DWI examination)

Key exclusion criteria

1.Those who noticeably deteriorated image quality due to physical movement during the process.
2.Those who discontinue the test due to claustrophobia.
3.Those who refuse to participate due to disclosure of research information.
4.Those who the research director judges to be inappropriate as a research target.

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Koji
Middle name
Last name Murakami

Organization

Juntendo University Hospital

Division name

Radiology

Zip code

113-8431

Address

3-1-3 Hongo, Bunkyo-ku, Tokyo

TEL

03-3813-3111

Email

k-murakami@juntendo.ac.jp


Public contact

Name of contact person

1st name Koji
Middle name
Last name Murakami

Organization

Juntendo University Hospital

Division name

Radiology

Zip code

113-8431

Address

3-1-3 Hongo, Bunkyo-ku, Tokyo

TEL

03-3813-3111

Homepage URL


Email

k-murakami@juntendo.ac.jp


Sponsor or person

Institute

Juntendo University

Institute

Department

Personal name



Funding Source

Organization

MEXT

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethics committee in Juntendo university hospital

Address

3-1-3 Hongo, Bunkyo-ku, Tokyo

Tel

03-3813-3111

Email

kenkyu5858@juntendo.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 06 Month 10 Day


Related information

URL releasing protocol

none

Publication of results

Unpublished


Result

URL related to results and publications

none

Number of participants that the trial has enrolled

26

Results

A weak correlation was observed between fibroscan and liver fibrosis markers and F IVIM, D*, suggesting that gender may be a confounding factor. IVIM-DWI alone should not be used as an index of liver cirrhosis, but should be comprehensively evaluated with other fibrosis markers and fibroscan.

Results date posted

2023 Year 06 Month 06 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

chronic hepatitis 26cases

Participant flow

MRI (IVIM-DWI) was performed and FIVIM, D*, and D values were measured. Furthermore, Fibroscan was performed and compared with the value of VCTE. We also measured liver fibrosis markers by blood test.

Adverse events

none

Outcome measures

Multivariate analysis of VCTE, an index of liver stiffness of Fibroscan, Type4 collagen, M2 GPI, P3P, FIB-4 index, an index of liver fibrosis, and F IVIM, D*, D values, an index of IVIM-DWI The relevance was analyzed.

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 06 Month 28 Day

Date of IRB

2019 Year 07 Month 25 Day

Anticipated trial start date

2019 Year 07 Month 25 Day

Last follow-up date

2021 Year 09 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2020 Year 06 Month 03 Day

Last modified on

2023 Year 12 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046290


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name